JP2019501198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501198A5 JP2019501198A5 JP2018535362A JP2018535362A JP2019501198A5 JP 2019501198 A5 JP2019501198 A5 JP 2019501198A5 JP 2018535362 A JP2018535362 A JP 2018535362A JP 2018535362 A JP2018535362 A JP 2018535362A JP 2019501198 A5 JP2019501198 A5 JP 2019501198A5
- Authority
- JP
- Japan
- Prior art keywords
- drug carrier
- ammonium
- cyclodextrin
- triethylammonium
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003937 drug carrier Substances 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 17
- 238000009472 formulation Methods 0.000 claims 12
- 239000002105 nanoparticle Substances 0.000 claims 11
- 229920000858 Cyclodextrin Polymers 0.000 claims 9
- 229910019142 PO4 Inorganic materials 0.000 claims 9
- 239000010452 phosphate Substances 0.000 claims 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 claims 9
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 239000001116 FEMA 4028 Substances 0.000 claims 6
- 239000000232 Lipid Bilayer Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 6
- 229960004853 betadex Drugs 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 208000010552 pancreatic tubular adenocarcinoma Diseases 0.000 claims 4
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 3
- SPIUHJINJWTDQE-UHFFFAOYSA-N cyclohexaamylose polysulfate Chemical compound O1C(C(C2OS(O)(=O)=O)OS(O)(=O)=O)C(COS(O)(=O)=O)OC2OC(C(C2OS(O)(=O)=O)OS(O)(=O)=O)C(COS(O)(=O)=O)OC2OC(C(C2OS(O)(=O)=O)OS(O)(=O)=O)C(COS(O)(=O)=O)OC2OC(C(OS(O)(=O)=O)C2OS(O)(=O)=O)C(COS(=O)(=O)O)OC2OC(C(C2OS(O)(=O)=O)OS(O)(=O)=O)C(COS(O)(=O)=O)OC2OC2C(OS(O)(=O)=O)C(OS(O)(=O)=O)C1OC2COS(O)(=O)=O SPIUHJINJWTDQE-UHFFFAOYSA-N 0.000 claims 3
- VHPVZEYUFNJLJZ-UHFFFAOYSA-N cyclooctaamylose polysulfate Chemical compound O1C(C(C2OS(O)(=O)=O)OS(O)(=O)=O)C(COS(O)(=O)=O)OC2OC(C(C2OS(O)(=O)=O)OS(O)(=O)=O)C(COS(O)(=O)=O)OC2OC(C(C2OS(O)(=O)=O)OS(O)(=O)=O)C(COS(O)(=O)=O)OC2OC(C(C2OS(O)(=O)=O)OS(O)(=O)=O)C(COS(O)(=O)=O)OC2OC(C(C2OS(O)(=O)=O)OS(O)(=O)=O)C(COS(O)(=O)=O)OC2OC(C(OS(O)(=O)=O)C2OS(O)(=O)=O)C(COS(=O)(=O)O)OC2OC(C(C2OS(O)(=O)=O)OS(O)(=O)=O)C(COS(O)(=O)=O)OC2OC2C(OS(O)(=O)=O)C(OS(O)(=O)=O)C1OC2COS(O)(=O)=O VHPVZEYUFNJLJZ-UHFFFAOYSA-N 0.000 claims 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 3
- 229960004768 irinotecan Drugs 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 239000002516 radical scavenger Substances 0.000 claims 3
- 239000000377 silicon dioxide Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- 206010006143 Brain stem glioma Diseases 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 2
- 150000003863 ammonium salts Chemical class 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 238000009104 chemotherapy regimen Methods 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 229920001427 mPEG Polymers 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- 239000011148 porous material Substances 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 claims 1
- ARLXEFZGGCEDPT-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylate;trimethylazanium Chemical compound C[NH+](C)C.C[NH+](C)C.C[NH+](C)C.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ARLXEFZGGCEDPT-UHFFFAOYSA-N 0.000 claims 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 claims 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims 1
- 239000005695 Ammonium acetate Substances 0.000 claims 1
- 239000004254 Ammonium phosphate Substances 0.000 claims 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical class CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229940043376 ammonium acetate Drugs 0.000 claims 1
- 235000019257 ammonium acetate Nutrition 0.000 claims 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 claims 1
- 235000019289 ammonium phosphates Nutrition 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical group N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
- 235000011130 ammonium sulphate Nutrition 0.000 claims 1
- 239000006177 biological buffer Substances 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- WORLLILUGHBXRR-UHFFFAOYSA-N n,n-diethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CCN(CC)CC.CCN(CC)CC.CCN(CC)CC.OC(=O)CC(O)(C(O)=O)CC(O)=O WORLLILUGHBXRR-UHFFFAOYSA-N 0.000 claims 1
- UBLQIESZTDNNAO-UHFFFAOYSA-N n,n-diethylethanamine;phosphoric acid Chemical compound [O-]P([O-])([O-])=O.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC UBLQIESZTDNNAO-UHFFFAOYSA-N 0.000 claims 1
- NKNFUMKGJYKPCT-UHFFFAOYSA-N n,n-diethylethanamine;sulfuric acid Chemical group [O-]S([O-])(=O)=O.CC[NH+](CC)CC.CC[NH+](CC)CC NKNFUMKGJYKPCT-UHFFFAOYSA-N 0.000 claims 1
- 239000002539 nanocarrier Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims 1
- XOYXELNNPALJIE-UHFFFAOYSA-N trimethylazanium phosphate Chemical compound C[NH+](C)C.C[NH+](C)C.C[NH+](C)C.[O-]P([O-])([O-])=O XOYXELNNPALJIE-UHFFFAOYSA-N 0.000 claims 1
- KYWVDGFGRYJLPE-UHFFFAOYSA-N trimethylazanium;acetate Chemical compound CN(C)C.CC(O)=O KYWVDGFGRYJLPE-UHFFFAOYSA-N 0.000 claims 1
- UWSCPROMPSAQOL-UHFFFAOYSA-N trimethylazanium;sulfate Chemical group CN(C)C.CN(C)C.OS(O)(=O)=O UWSCPROMPSAQOL-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022072344A JP7636805B2 (ja) | 2016-01-08 | 2022-04-26 | カーゴ送達のための、脂質二重層コーティングを備えたメソ多孔性シリカナノ粒子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276634P | 2016-01-08 | 2016-01-08 | |
| US62/276,634 | 2016-01-08 | ||
| PCT/US2017/012625 WO2017120537A1 (en) | 2016-01-08 | 2017-01-06 | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022072344A Division JP7636805B2 (ja) | 2016-01-08 | 2022-04-26 | カーゴ送達のための、脂質二重層コーティングを備えたメソ多孔性シリカナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501198A JP2019501198A (ja) | 2019-01-17 |
| JP2019501198A5 true JP2019501198A5 (https=) | 2020-01-30 |
| JP7068173B2 JP7068173B2 (ja) | 2022-05-16 |
Family
ID=59274072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535362A Active JP7068173B2 (ja) | 2016-01-08 | 2017-01-06 | カーゴ送達のための、脂質二重層コーティングを備えたメソ多孔性シリカナノ粒子 |
| JP2022072344A Active JP7636805B2 (ja) | 2016-01-08 | 2022-04-26 | カーゴ送達のための、脂質二重層コーティングを備えたメソ多孔性シリカナノ粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022072344A Active JP7636805B2 (ja) | 2016-01-08 | 2022-04-26 | カーゴ送達のための、脂質二重層コーティングを備えたメソ多孔性シリカナノ粒子 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10143660B2 (https=) |
| EP (2) | EP3399966B1 (https=) |
| JP (2) | JP7068173B2 (https=) |
| KR (3) | KR102408525B1 (https=) |
| CN (1) | CN108601746B (https=) |
| AU (3) | AU2017206077B2 (https=) |
| CA (1) | CA3010711A1 (https=) |
| WO (1) | WO2017120537A1 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4378461A3 (en) | 2013-03-05 | 2024-09-11 | The Regents of University of California | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents |
| EP3270932B1 (en) | 2015-03-16 | 2024-08-21 | PDX Pharmaceuticals, Inc. | Cross-linked polymer modified nanoparticles |
| CN108601746B (zh) | 2016-01-08 | 2024-09-13 | 加利福尼亚大学董事会 | 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒 |
| AU2017269335B2 (en) | 2016-05-26 | 2021-07-01 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| CN110446501A (zh) | 2017-03-09 | 2019-11-12 | 代阿麦迪卡股份有限公司 | 组织激肽释放酶1的剂型 |
| US11306111B2 (en) | 2017-07-31 | 2022-04-19 | January Therapeutics, Inc. | Organophosphate derivatives |
| US12383499B2 (en) | 2018-01-01 | 2025-08-12 | The Regents Of The University Of California | Scale up synthesis of silicasome nanocarriers |
| CN108562737A (zh) * | 2018-01-12 | 2018-09-21 | 天津大学 | 用阳离子脂质体包裹负载钙黄绿素的介孔二氧化硅纳米颗粒的制备方法 |
| US12208138B2 (en) * | 2018-02-19 | 2025-01-28 | Boise State University | Radiation-triggered liposomes |
| US20210007999A1 (en) * | 2018-03-02 | 2021-01-14 | January Therapeutics, Inc. | Nanoparticle compositions |
| CN112004527B (zh) * | 2018-04-23 | 2024-09-24 | 盈擘生技股份有限公司 | 用于治疗肺部疾病的可吸入脂质体缓释组合物 |
| WO2020055713A1 (en) * | 2018-09-10 | 2020-03-19 | Taiwan Liposome Co., Ltd. | Sustained-release ophthalmic pharmaceutical compositions and uses thereof |
| CA3115355A1 (en) | 2018-10-16 | 2020-04-23 | Silicycle Inc. | Tunable process for silica capsules/spheres preparation and their use |
| TWI767149B (zh) * | 2018-10-17 | 2022-06-11 | 台灣微脂體股份有限公司 | 含有免疫調節劑的緩釋藥物組合物及其用途 |
| CN109557158B (zh) * | 2018-12-12 | 2020-12-08 | 郑州大学 | 酶固定基质在有机磷杀虫剂生物检测领域中的应用 |
| US12351653B1 (en) | 2019-03-08 | 2025-07-08 | Lisata Therapeutics, Inc. | Pharmaceutical compositions comprising novel cyclic peptides |
| EP3714879A1 (en) | 2019-03-28 | 2020-09-30 | Sisaf Ltd | Structured encapsulated silicon-containing particles |
| GB201904334D0 (en) | 2019-03-28 | 2019-05-15 | Sisaf Ltd | Carrier system for preparing herbaceous extracts |
| GB201904336D0 (en) | 2019-03-28 | 2019-05-15 | Sisaf Ltd | A delivery system |
| GB201904337D0 (en) | 2019-03-28 | 2019-05-15 | Sisaf Ltd | A delivery system |
| GB201904338D0 (en) * | 2019-03-28 | 2019-05-15 | Sisaf Ltd | Fluorouracil-containing formulations |
| CN113874029B (zh) | 2019-04-01 | 2025-02-11 | 汉阳大学校产学协力团 | 基于cp2c靶向肽的抗癌剂 |
| WO2020236305A1 (en) * | 2019-05-20 | 2020-11-26 | Board Of Regents Of The University Of Texas System | Formulations of cyclic macromolecule-based nanoparticles encapsulating small molecules |
| WO2021011501A1 (en) * | 2019-07-12 | 2021-01-21 | Oregon Health & Science University | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor |
| US20220249389A1 (en) | 2019-07-12 | 2022-08-11 | Oregon Health & Science University | Immunotherapeutic constructs and methods of their use |
| US11708637B2 (en) | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
| CN110548029B (zh) * | 2019-10-09 | 2022-08-16 | 上海交通大学医学院 | 甲磺酸奥希替尼在制备治疗真菌感染药物中的应用 |
| CN111074282B (zh) * | 2019-10-15 | 2021-11-05 | 东营施普瑞石油工程技术有限公司 | 一种pH响应型可降解智能缓蚀剂、制备方法及其应用 |
| CN110559280B (zh) * | 2019-10-16 | 2021-06-25 | 中国人民解放军军事科学院军事医学研究院 | 治疗肺癌的载紫杉醇脂质体细菌吸入制剂 |
| AU2021266721A1 (en) * | 2020-05-04 | 2022-12-08 | Lisata Therapeutics Australia Pty Ltd. | Methods for treating pancreatic cancer and other solid tumors |
| WO2021226368A1 (en) * | 2020-05-06 | 2021-11-11 | Nanotech Pharma Inc. | Liposome formulations for treatment of cancers and drug resistance of cancers |
| EP4171605A4 (en) * | 2020-06-30 | 2024-11-27 | The Regents Of The University Of California | GSK3 INHIBITOR-LOADED NANOFORMULATIONS AS CANCER IMMUNOTHERAPY |
| WO2022115075A1 (en) * | 2020-11-30 | 2022-06-02 | Ege Üni̇versi̇tesi̇ | Targeted nanoparticles carrying dual drugs in the treatment of melanoma |
| WO2022132748A1 (en) * | 2020-12-14 | 2022-06-23 | Bps Just Energy Technology, Llc | Antimicrobial compositions with supramolecular structures |
| US20220378711A1 (en) * | 2021-05-11 | 2022-12-01 | United States Government As Represented By The Department Of Veterans Affairs | PH-Responsive Nanoparticles for Treating Cancer |
| CN113521035B (zh) * | 2021-08-05 | 2023-04-25 | 河南大学 | 化学免疫联合治疗纳米药物的制备方法及应用 |
| CN115960160B (zh) * | 2021-10-12 | 2024-07-16 | 南京大学 | 活细胞膜整合素αvβ3聚糖的原位糖链延长方法 |
| WO2023064887A1 (en) | 2021-10-15 | 2023-04-20 | The Board Of Trustees Of The University Of Illinois | Mechanochemical dynamic therapy for focal cancer treatment |
| CN114487083B (zh) * | 2022-01-19 | 2024-05-07 | 中国地质大学（北京） | 一种磁性羟基纳米材料Fe3O4@COFs及其在磺胺质谱检测领域的应用 |
| US20250177303A1 (en) * | 2022-03-10 | 2025-06-05 | The Regents Of The University Of California | A drug nanocarrier system to deliver a combination of tlr agonists and/or a lipoxin plus immunogenic cell death inducing chemotherapeutic agents for cancer immunotherapy |
| CN114796055B (zh) * | 2022-05-19 | 2023-08-15 | 广东艾粒生物科技有限责任公司 | 富含脂质体纳米粒的美白敷料及其制备方法 |
| WO2024035784A1 (en) * | 2022-08-10 | 2024-02-15 | Auburn University | Shrinking nanomaterial for biomedical applications |
| US20260069713A1 (en) * | 2022-08-29 | 2026-03-12 | Vivasor, Inc. | Lipid-Coated Nanoparticles |
| CN115636885B (zh) * | 2022-10-26 | 2023-08-11 | 湖北中医药大学 | 一种季铵环糊精及其制备方法和应用、银纳米粒子环糊精复合物及其制备方法和应用 |
| EP4364726A1 (en) * | 2022-11-02 | 2024-05-08 | Nano Targeting & Therapy Biopharma Inc. | Method for treating a cancer and/or cancer metastasis |
| JP2026501821A (ja) * | 2023-01-08 | 2026-01-16 | アティヴァーレ セラピューティクス インコーポレイテッド | 免疫調節系としてメソポーラスシリカロッドを使用したサイトカインの腫瘍間送達および腫瘍内送達 |
| CN121194787A (zh) * | 2023-04-13 | 2025-12-23 | 伊迪亚生物科学公司 | 包含mat2a抑制剂和拓扑异构酶抑制剂、剪接抑制剂磺酰胺或kif18抑制剂的组合疗法 |
| KR102666470B1 (ko) * | 2023-05-04 | 2024-05-17 | 주식회사 아리바이오 | 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물 |
| KR102666469B1 (ko) * | 2023-05-04 | 2024-05-17 | 주식회사 아리바이오 | 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물 |
| IT202300015396A1 (it) * | 2023-07-21 | 2025-01-21 | Torino Politecnico | Nanoparticelle rivestite e loro uso per il trasporto di agenti terapeutici e diagnostici |
| US12102693B1 (en) * | 2023-08-25 | 2024-10-01 | Nanomedtrix, Llc | Pharmaceutical composition with nanoparticle-based drug delivery combined with non-invasive radiographic monitoring model |
| KR102647264B1 (ko) * | 2023-11-01 | 2024-03-14 | 주식회사 아리바이오 | 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물 |
| WO2025100777A1 (ko) * | 2023-11-08 | 2025-05-15 | 주식회사 엔테라퓨틱스 | 표면이 개질된 나노입자 및 이의 약물 전달 용도 |
| CN117797833A (zh) * | 2023-12-14 | 2024-04-02 | 苏州大学 | 含钼纳米材料作为脂氧合酶的应用 |
| WO2025179264A1 (en) * | 2024-02-22 | 2025-08-28 | President And Fellows Of Harvard College | Functionalized silica nanoparticles and methods of making and using the same |
| CN119236105B (zh) * | 2024-09-29 | 2025-09-05 | 中南大学 | 一种基于铜死亡的多功能抗肿瘤纳米药物递送系统及其制备方法与应用 |
| US12390420B1 (en) | 2024-10-22 | 2025-08-19 | Bryet Us, Inc. | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993754A (en) | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
| CH624011A5 (https=) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
| US4885172A (en) | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE4217353B4 (de) | 1992-05-26 | 2008-02-21 | Nimbus Biotechnologie Gmbh | Verfahren zur säulenchromatographischen Trennung von Proteinen mittels Lipidbilayer-beschichteter Silicagele |
| US5827533A (en) | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| DE19814775C2 (de) | 1998-04-02 | 2001-04-19 | Nimbus Biotechnologie Gmbh | Verfahren zur Bestimmung der Lipid-Bindungskonstanten von Substanzen in wässriger Lösung an Oberflächen aus amphiphilen Molekülen |
| US7618565B2 (en) | 2001-08-16 | 2009-11-17 | Polytechnic Institute Of New York University | Lipobeads and their production |
| US20040005352A1 (en) | 2002-04-16 | 2004-01-08 | Lopez Gabriel P. | Biologically functionalized porous microspheres |
| AU2003268087A1 (en) | 2002-08-23 | 2004-03-11 | Ian Ma | Liposomal gemcitabine compositions for better drug delivery |
| US7563451B2 (en) | 2003-07-22 | 2009-07-21 | Iowa State University Research Foundation, Inc. | Capped mesoporous silicates |
| CA2928387A1 (en) * | 2004-05-03 | 2005-11-17 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
| MX2007001362A (es) | 2004-08-03 | 2007-04-16 | Chemetall Gmbh | Procedimiento para revestir superficies metalicas con un revestimiento anticorrosivo. |
| EP1796689A4 (en) | 2004-09-20 | 2009-01-14 | British Columbia Cancer Agency | FREE OR LIPOSOMAL GEMCITABIN ALONE OR COMBINED WITH FREE OR LIPOSOMAL IDARUBICIN |
| US20110104073A1 (en) | 2007-01-18 | 2011-05-05 | Qi Zeng | Iron/Iron Oxide Nanoparticle and Use Thereof |
| US9993437B2 (en) | 2007-12-06 | 2018-06-12 | The Regents Of The University Of California | Mesoporous silica nanoparticles for biomedical applications |
| US20100284924A1 (en) | 2008-01-23 | 2010-11-11 | The Regents Of The University Of California | Nano-devices having impellers for capture and release of molecules |
| US20100310465A1 (en) | 2008-01-23 | 2010-12-09 | The Regents Of The University Of California | Nano-devices having releasable seals for controlled release of molecules |
| US20120021034A1 (en) | 2008-12-19 | 2012-01-26 | The Regents Of The University Of California | Structured silver-mesoporous silica nanoparticles having antimicrobial activity |
| WO2010078569A2 (en) | 2009-01-05 | 2010-07-08 | Stc.Unm | Porous nanoparticle supported lipid bilayer nanostructures |
| US8992984B1 (en) * | 2009-10-21 | 2015-03-31 | Stc.Unm | Protocells and their use for targeted delivery of multicomponent cargos to cancer cells |
| TWI383808B (zh) | 2009-11-23 | 2013-02-01 | 國立清華大學 | 磷脂質包覆中孔洞二氧化矽奈米球的合成與其生醫應用 |
| WO2012009448A2 (en) | 2010-07-13 | 2012-01-19 | The Regents Of The University Of California | Cationic polymer coated mesoporous silica nanoparticles and uses thereof |
| US20120207795A1 (en) | 2010-07-13 | 2012-08-16 | The Regents Of The University Of California | Cationic polymer coated mesoporous silica nanoparticles and uses thereof |
| AU2012249474A1 (en) | 2011-04-28 | 2013-11-07 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
| US10220004B2 (en) | 2011-07-14 | 2019-03-05 | The Regents Of The University Of California | Method of controlled delivery using sub-micron-scale machines |
| BR112014001346A8 (pt) | 2011-07-19 | 2018-05-08 | Stc Unm | composto nanotransportador, método, composto farmacêutico e uso de um composto |
| JP2014532071A (ja) * | 2011-10-14 | 2014-12-04 | エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ | カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法 |
| US8926994B2 (en) | 2011-12-07 | 2015-01-06 | The Methodist Hospital Research Institute | Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity |
| WO2014081827A1 (en) | 2012-11-20 | 2014-05-30 | Mpt, Inc. | Advertising media and method and system for applying advertising media |
| EP4378461A3 (en) * | 2013-03-05 | 2024-09-11 | The Regents of University of California | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents |
| EP3270932B1 (en) | 2015-03-16 | 2024-08-21 | PDX Pharmaceuticals, Inc. | Cross-linked polymer modified nanoparticles |
| LU92784B1 (en) | 2015-07-22 | 2017-01-31 | Luxembourg Inst Of Science And Tech (List) | Negatively charged self-assembling supported lipid bilayer on mesoporous silica nanoparticles, method of synthesis and use as a nanovector |
| CN108601746B (zh) | 2016-01-08 | 2024-09-13 | 加利福尼亚大学董事会 | 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒 |
| US12383499B2 (en) | 2018-01-01 | 2025-08-12 | The Regents Of The University Of California | Scale up synthesis of silicasome nanocarriers |
-
2017
- 2017-01-06 CN CN201780010248.8A patent/CN108601746B/zh active Active
- 2017-01-06 JP JP2018535362A patent/JP7068173B2/ja active Active
- 2017-01-06 KR KR1020187022622A patent/KR102408525B1/ko active Active
- 2017-01-06 AU AU2017206077A patent/AU2017206077B2/en active Active
- 2017-01-06 EP EP17736481.7A patent/EP3399966B1/en active Active
- 2017-01-06 WO PCT/US2017/012625 patent/WO2017120537A1/en not_active Ceased
- 2017-01-06 KR KR1020247013856A patent/KR20240064009A/ko not_active Ceased
- 2017-01-06 KR KR1020227019372A patent/KR20220085840A/ko not_active Ceased
- 2017-01-06 CA CA3010711A patent/CA3010711A1/en active Pending
- 2017-01-06 EP EP23158990.4A patent/EP4218739A3/en active Pending
- 2017-10-30 US US15/798,287 patent/US10143660B2/en active Active
-
2018
- 2018-10-18 US US16/164,030 patent/US10765636B2/en active Active
-
2020
- 2020-08-05 US US16/947,539 patent/US11096900B2/en active Active
-
2021
- 2021-07-23 US US17/384,214 patent/US12171884B2/en active Active
-
2022
- 2022-02-10 AU AU2022200881A patent/AU2022200881B2/en active Active
- 2022-04-26 JP JP2022072344A patent/JP7636805B2/ja active Active
-
2023
- 2023-09-18 AU AU2023233055A patent/AU2023233055B2/en not_active Expired - Fee Related
-
2024
- 2024-11-01 US US18/935,112 patent/US20250281417A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501198A5 (https=) | ||
| Pillai | Nanotechnology toward treating cancer: A comprehensive review | |
| Poon et al. | Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer | |
| JP2016529284A5 (https=) | ||
| Lasa-Saracibar et al. | Lipid nanoparticles for cancer therapy: state of the art and future prospects | |
| US11357724B2 (en) | Pharmaceutical composition, preparation and uses thereof | |
| JP2015523355A5 (https=) | ||
| TW202529777A (zh) | 組合療法 | |
| Zhu et al. | Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation | |
| KR20190018052A (ko) | 표적화된 치료 나노입자 및 그의 제조 및 사용 방법 | |
| Yadav et al. | Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers) | |
| Mao et al. | Development of a stable single-vial liposomal formulation for vincristine | |
| JP6263609B2 (ja) | リポソーム組成物及びその製造方法 | |
| Tan et al. | Preparation of vincristine sulfate-loaded poly (butylcyanoacrylate) nanoparticles modified with pluronic F127 and evaluation of their lymphatic tissue targeting | |
| Gajera et al. | An overview of FDA approved liposome formulations for cancer therapy | |
| Mussi et al. | Improved pharmacokinetics and enhanced tumor growth inhibition using a nanostructured lipid carrier loaded with doxorubicin and modified with a layer-by-layer polyelectrolyte coating | |
| JP6986563B2 (ja) | ｂｃｌ−２を抑制するアンチセンスオリゴヌクレオチドの脂質ナノ粒子及びその調製方法 | |
| JP2017513938A5 (https=) | ||
| EP4353223A1 (en) | Application of pharmaceutical composition having specific drug-to-lipid ratio in antitumor | |
| JP5336466B2 (ja) | コレスタノール誘導体の併用用途 | |
| CN113616618B (zh) | 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒 | |
| WO2005092388A1 (ja) | リポソーム製剤 | |
| JP5466174B2 (ja) | 水溶性、カチオン性および両親媒性の薬学的に活性な物質を投与するためのドラッグ・デリバリー・システム | |
| EP3213755B1 (en) | New production method of lipoplex for local administration and antitumor drug using lipoplex | |
| CN105796495A (zh) | 一种盐酸伊立替康脂质体药物组合物及其制备方法 |